Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3921 (Unasnemab) in acute traumatic cervical spinal cord injury
NCT04683848Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of unasnemab in spinal cord injury (SCI), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Aug 2021; status: completed.
02
Drugs
unasnemab
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04683848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683848.